Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica
    Journal:  Drug-drug interactions of simnotrelvir/ritonavir: an open-lable, fixed-sequence, two-period clinical trial. (Pubmed Central) -  Sep 21, 2024   
    P1
    The co-administration of simnotrelvir/ritonavir with CYP3A and P-gp inhibitors can be safely used, while the co-administration with CYP3A and P-gp strong inducer should be avoided to minimize the risk of under-exposure. Co-administration of midazolam with simnotrelvir/ritonavir increased systemic exposure of midazolam.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Effect of use of oral antiviral agents on reducing critical illness and mortality for patients with moderate to severe COVID-19 (PS-25; Poster board no. 11) -  May 31, 2024 - Abstract #ERS2024ERS_5025;    
    No adverse drug reactions were observed during hospitalization, and no new safety events were observed, suggesting the excellent effectiveness and safety of Simnotrelvir/Ritonavir and Nirmatrelvir/Ritonavir in preventing the progression of medium-sized COVID-19 to severe disease. Administering simnotrelvir/ritonavir and nirmatrelvir/ritonavir reduced the risk of moderate to severe COVID-19 patients progressing to critical illness and mortality.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Retrospective analysis on Nirmatrelvir versus Simnotrelvir for adults with moderate to severe COVID-19. (PS-26; Poster board no. 17) -  May 31, 2024 - Abstract #ERS2024ERS_1624;    
    The overall efficacy of the two drugs is comparable, treatment choice should be based on the individual patient's situation and resistance status. These findings provide reference information for clinicians when selecting antiviral treatment regimens.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Outcomes of two kinds of 3CLpro inhibitors in delayed treatment of COVID-19 patients with diabetes (PS-26; Poster board no. 16) -  May 31, 2024 - Abstract #ERS2024ERS_1623;    
    These findings provide reference information for clinicians when selecting antiviral treatment regimens. Compared with Nirmatrelvir/ritonavir, Simnotrelvir/ritonavir is more suitable for antiviral treatment of COVID-19 patients with diabetes.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Thiophene-fused ?-lactams inhibit the SARS-CoV-2 main protease via reversible covalent acylation. (Pubmed Central) -  May 24, 2024   
    We report combined structure activity relationship and mass spectrometric studies revealing that appropriately functionalized ?-lactams can potently inhibit Mpro by reversible covalent reaction with Cys145 of Mpro. The results suggest that ?-lactams have potential as electrophilic warheads for development of covalently reacting small-molecule inhibitors of Mpro and, by implication, other nucleophilic cysteine enzymes.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica
    Journal:  Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply. (Pubmed Central) -  Apr 24, 2024   
    The results suggest that ?-lactams have potential as electrophilic warheads for development of covalently reacting small-molecule inhibitors of Mpro and, by implication, other nucleophilic cysteine enzymes. No abstract available
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica
    Journal:  Simnotrelvir as a potential treatment for COVID-19. (Pubmed Central) -  Feb 23, 2024   
    Simnotrelvir appears to be effective in standard-risk patients, including those who have completed primary vaccination against COVID-19 and have received a booster dose. This manuscript examines the rationale for the development of simnotrelvir and explores how this drug may be used in the future to treat COVID-19.
  • ||||||||||  Review, Journal:  Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116). (Pubmed Central) -  Feb 14, 2024   
    So far, a few small-molecule antiviral drugs, including nirmatrelvir-ritonavir (Paxlovid), remdesivir, and molnupiravir have been marketed for the treatment of COVID-19...These drugs include azvudine, simnotrelvir-ritonavir (Xiannuoxin), leritrelvir, and mindeudesivir (VV116)...In this review, we discuss the most recent findings regarding the pharmacological mechanism and therapeutic effects focusing on mindeudesivir and other small-molecule antiviral agents for COVID-19. These findings will expand our understanding and highlight the potential widespread application of China's homegrown anti-COVID-19 drugs.
  • ||||||||||  Review, Journal:  On the origins of SARS-CoV-2 main protease inhibitors. (Pubmed Central) -  Jan 29, 2024   
    Since many series of covalent SARS-CoV-2-M inhibitors owe some of their origins to previous work on other proteases, we first provided a description of various inhibitors of cysteine-bearing human caspase-1 or cathepsin K, as well as inhibitors of serine proteases such as human dipeptidyl peptidase-4 or the hepatitis C protein complex NS3/4A. This is then followed by a description of the results of the approaches adopted (repurposing, structure-based and high throughput screening) to discover coronavirus main protease inhibitors.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica
    Journal:  Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. (Pubmed Central) -  Jan 21, 2024   
    P2/3
    Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns. (Funded by Jiangsu Simcere Pharmaceutical; ClinicalTrials.gov number, NCT05506176.).
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica
    Journal:  RNA: The most attractive target in recent viral diseases. (Pubmed Central) -  Jan 18, 2024   
    These strategies act by taking advantage of the weakness points of this attractive bioweapon to disable or attack it (itself), accordingly stop the entire viral reproduction, and effectively end the severe microbial infections such as the coronavirus disease 2019 (COVID-19). The generation of respective slightly falsely-weaved RNA strands, either endogenously or exogenously, is the principal key for designing most of these therapeutic approaches.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Victrelis (boceprevir) / Roche, Merck (MSD)
    Preclinical, Journal:  Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. (Pubmed Central) -  Nov 3, 2023   
    It effectively blocks replications of SARS-CoV-2 variants in cell-based assays and exhibits good pharmacokinetic and safety profiles in male and female rats and monkeys, leading to robust oral efficacy in a male mouse model of SARS-CoV-2 Delta infection in which it not only significantly reduces lung viral loads but also eliminates the virus from brains. The discovery of simnotrelvir thereby highlights the utility of structure-based development of marked protease inhibitors for providing a small molecule therapeutic effectively combatting human coronaviruses.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Mindewei (deuremidevir) / Shanghai Junshi Biosci, Vigonvita Life Sci
    Journal:  Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19. (Pubmed Central) -  Sep 14, 2023   
    Simnotrelvir is an oral antiviral agent targeting the 3-chymotrypsin-like protease, which is essential for SARS-CoV-2 viral replication. Previous clinical trials revealed that both deuremidevir and simnotrelvir-ritonavir were effective and well tolerated in the treatment of COVID-19.
  • ||||||||||  SIM0417 / Simcere, Shanghai Inst. of Materia Medica
    Trial completion, Trial completion date:  To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 (clinicaltrials.gov) -  May 31, 2023   
    P1/2,  N=32, Completed, 
    The efficacy of SIM0417 showed a monotonic dose-response relationship, and the 750 Recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022
  • ||||||||||  SIM0417 / Simcere, Shanghai Inst. of Materia Medica
    Enrollment open:  To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 (clinicaltrials.gov) -  May 16, 2022   
    P1/2,  N=32, Recruiting, 
    Not yet recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  SIM0417 / Simcere, Shanghai Inst. of Materia Medica
    New P2/3 trial, Combination therapy:  To Evaluate SSD8432/Ritonavir in Adults With COVID-19 (clinicaltrials.gov) -  May 13, 2022   
    P2/3,  N=670, Not yet recruiting, 
  • ||||||||||  SIM0417 / Simcere, Shanghai Inst. of Materia Medica
    New P1/2 trial:  To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 (clinicaltrials.gov) -  May 11, 2022   
    P1/2,  N=32, Not yet recruiting,